An open-label, prospective, observational study of the incidence of coronary artery disease in patients with hiv infection receiving highly active antiretroviral therapy
- 1 September 2003
- journal article
- clinical trial
- Published by Elsevier in Clinical Therapeutics
- Vol. 25 (9), 2405-2418
- https://doi.org/10.1016/s0149-2918(03)80283-7
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD studyAIDS, 2003
- Cardiovascular and Cerebrovascular Events in Patients Treated for Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 2003
- Protease inhibitors and cardiovascular outcomes in patients with HIV-1The Lancet, 2002
- HIV Protease Inhibitor Ritonavir Induces Cytotoxicity of Human Endothelial CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Cardiovascular Manifestations of HIV InfectionCirculation, 2002
- Use of Human Immunodeficiency Virus-1 Protease Inhibitors Is Associated With Atherogenic Lipoprotein Changes and Endothelial DysfunctionCirculation, 2001
- Effects of Protease Inhibitors on Hyperglycemia, Hyperlipidemia, and LipodystrophyArchives of Internal Medicine, 2000
- HIV Protease Inhibitor-Related Lipodystrophy SyndromeClinical Infectious Diseases, 2000
- Unstable angina. A classification.Circulation, 1989
- Chapter 1: PressuresEuropean Heart Journal, 1985